New macrolide, lincosaminide and streptogramin B antibiotics

Bibliography

• Kirst HA. Aminoglycoside, macrolide, glycopeptide, and miscellaneous antibacterial antibiotics. In: Wolff ME, editor, Burger's medicinal chemistry and drug discovery. 5th edition. Volume 2. John Wiley & Sons; 1996. p. 463-525
   Google Scholar
• Kaneko T, Dougherty TJ, Magee TV. Macrolide antibiotics. In: Taylor JB, Triggle DJ, editors, Comprehensive medicinal chemistry II. Volume 7. Elsevier; 2007. p. 519-66
   Google Scholar
• Kirst HA. Antibiotics (macrolides). In: Seidel A, editor, Kirk-Othmer encyclopedia of chemical technology. 5th edition. Volume 15. John Wiley & Sons; 2005. p. 271-320
   Google Scholar
• Sivapalasingam S, Steigbigel NH. Macrolides, clindamycin, and ketolides. In: Mandell GL, Bennett JE, Dolin R, editors, Mandell, Douglas, and Bennett's principles and practice of infectious diseases (Chapter 30). 7th edition. Volume 1. Churchill Livingstone; 2009
   Google Scholar
• Mulazimoglu L, Tulkens PM, Van Bambeke F. Macrolides. In: Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, editors, Antimicrobial therapy and vaccines. 2nd edition. Volume 2. ESun Technologies; 2005. p. 243-80
   Google Scholar
• Agouridas C, Benedetti Y, Denis A, Ketolides, a new distinct semi-synthetic class of macrolides. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, FL; 1994. p. F-164
   Google Scholar
• Agouridas C, Benedetti Y, Denis A, Ketolides, a new distinct class of macrolide antibacterials. Synthesis and structural characteristics of RU 004. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 1995. p. F-157
   Google Scholar
• Bryskier A, Denis A. Ketolides: novel antibacterial agents designed to overcome resistance to erythromycin A within gram-positive cocci. In: Schonfeld W, Kirst HA, editors, Macrolide antibiotics. Birkhauser Verlag; 2002. p. 97-140
   Google Scholar
• Reinert RR. Clinical efficacy of ketolides in the treatment of respiratory tract infections. J Antimicrob Chemother 2004;53:918-27
   Google Scholar
• Wellington K, Noble S. Telithromycin. Drugs 2004;64:1683-94
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Neuhauser MM. Ketolides (telithromycin, cethromycin). In: Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, editors, Antimicrobial therapy and vaccines. 2nd edition. Volume 2. ESun Technologies; 2005. p. 201-22
   Google Scholar
• Van Bambeke F, Harms JM, Van Laethem Y, Tulkens PM. Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections. Expert Opin Pharmacother 2008;9:267-83
   PubMed Web of Science ®Google Scholar
• Kaye D. U. S. limits use of risky Sanofi antibiotic Ketek. Clin Infect Dis 2007;44:iv
   Google Scholar
• Soreth J, Cox E, Kweder S, Ketek – the FDA perspective. N Engl J Med 2007;356:1675-6
   PubMed Web of Science ®Google Scholar
• Ross DB. The FDA and the case of Ketek. N Engl J Med 2007;356:1601-4
   PubMed Web of Science ®Google Scholar
• Hammerschlag MR, Sharma R. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections. Expert Opin Investig Drugs 2008;17:387-400
   PubMed Web of Science ®Google Scholar
• Anonymous. Cethromycin: A-195773, A-195773-0, A-1957730, Abbott-195773, ABT 773. Drugs 2007;8:95-102
   Google Scholar
• Available from: http://www.advancedlifesciences.com
   Google Scholar
• Wang G, Niu D, Qiu Y-L, Synthesis of novel 6,11-O-bridged bicyclic ketolides via a palladium-catalyzed bis-allylation. Org Lett 2004;6:4455-8
   Google Scholar
• Jiang L-J, Wang M, Or YS. Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers. Antimicrob Agents Chemother 2009;53:1786-92
   Google Scholar
• Jiang L-J, Or YS. Pharmacokinetics of EDP-420 after multiple oral doses in healthy adult volunteers and in a bioequivalence study. Antimicrob Agents Chemother 2009;53:3218-25
   Google Scholar
• Furuie H, Saisho Y, Yoshikawa T, Shimada J. Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects. Antimicrob Agents Chemother 2010;54:866-70
   Google Scholar
• Available from: http://www.enanta.com
   Google Scholar
• Liang C-H, Yao S, Chiu Y-H, Synthesis and biological activity of new 5-O-sugar modified ketolide and 2-fluoro-ketolide antibiotics. Bioorg Med Chem Lett 2005;15:1307-10
   PubMed Web of Science ®Google Scholar
• Romero A, Liang C-H, Chiu Y-H, An efficient entry to new sugar modified ketolide antibiotics. Tetrahedron Lett 2005;46:1483-7
   Web of Science ®Google Scholar
• Optimer Pharmaceuticals, Inc. Novel antibacterial agents. WO2004080391; 2004
   Google Scholar
• Woosley LN, Castanheira M, Jones RN. CEM-101 activity against gram-positive organisms. Antimicrob Agents Chemother 2010;54:2182-7
   PubMed Web of Science ®Google Scholar
• McGhee P, Clark C, Kosowska-Shick KM, In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. Antimicrob Agents Chemother 2010;54:230-8
   PubMed Web of Science ®Google Scholar
• Available from: http://www.cempra.com
   Google Scholar
• Bertrand D, Bertrand S, Fernandes P. Proposed mechanisms to explain the unusual visual disturbances associated with telithromycin. 49th Interscience Conference on Antimicrobial Agents Chemotherapy. San Francisco, CA; 2009. p. A1-580
   Google Scholar
• Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents. WO2009055557; 2009
   Google Scholar
• Mullins LM, Huband MD, McCurdy SP, In vitro and in vivo antibacterial activity of PF-04287881: a new ketolide antimicrobial against recent bacterial clinical isolates. 49th Interscience Conference on Antimicrobial Agents Chemotherapy. San Francisco, CA; 2009. p. F1-2042
   Google Scholar
• Pfizer Products, Inc. Erythromycin-based macrolides. WO2008110918; 2008
   Google Scholar
• Magee TV, Ripp SL, Li B, Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections. J Med Chem 2009;52:7446-57
   PubMed Web of Science ®Google Scholar
• Available from: http://www.pfizer.com
   Google Scholar
• Flanagan ME, Chupak L, Dougherty TJ, New series of azetidinyl ketolide sulfonamides: structure activity relationships and identification of PF-03438011 and PF-03438012. 49th Interscience Conference on Antimicrobial Agents Chemotherapy. San Francisco, CA; 2009. p. F1-2041
   Google Scholar
• Pfizer Products, Inc. Macrolides. WO2006067589; 2006
   Google Scholar
• Kouvela EC, Kalpaxis DL, Wilson DN, Dinos GP. Distinct mode of interaction of a novel ketolide antibiotic that displays enhanced antimicrobial activity. Antimicrob Agents Chemother 2009;53:1411-9
   PubMed Web of Science ®Google Scholar
• Kosan Biosciences, Inc. Amido macrolides. WO2003061671; 2003
   Google Scholar
• Kosan Biosciences, Inc. 7-Quinolyl ketolide antibacterial agents. WO2007/070536; 2007
   Google Scholar
• Ward SL, Desai RP, Hu Z, Precursor-directed biosynthesis of 6-deoxyerythronolide B analogues is improved by removal of the initial catalytic sites of the polyketide synthase. J Ind Microbiol Biotechnol 2007;34:9-15
   Google Scholar
• Pal S. A journey across the sequential development of macrolides and ketolides related to erythromycin. Tetrahedron 2006;62:3171-200
   Web of Science ®Google Scholar
• Xu P, Liu L, Chen X-Z, Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity. Bioorg Med Chem Lett 2009;19:4079-83
   Google Scholar
• Kaneko T, Romero K, Li B, Buzon R. Novel tethers in ketolide antibiotics. Bioorg Med Chem Lett 2007;17:5049-53
   PubMed Web of Science ®Google Scholar
• Taisho Pharmaceutical Co., Ltd. 2-Fluoro-6-O-substituted ketolide derivative. WO2005087787; 2005
   Google Scholar
• Taisho Pharmaceutical Co., Ltd. 6-O-Substituted ketolide derivatives. WO2005075495; 2005
   Google Scholar
• Bhateja P, Barman T, Singhal S, In vitro and in vivo efficacy of novel ketolide RBx YSB 93019 and comparison with telithromycin. 49th Interscience Conference on Antimicrobial Agents Chemotherapy. San Francisco, CA; 2009. p. F1-2046
   Google Scholar
• Ranbaxy Laboratories Ltd. Ketolide derivatives as antibacterial agents. WO2007060518; 2007
   Google Scholar
• Pfizer, Inc. Macrolide antibiotics. US6809080; 2004
   Google Scholar
• Kaneko T, McMillen W, Lynch MK. Synthesis and antibacterial activity of C11, C12-cyclic urea analogues of ketolides. Bioorg Med Chem Lett 2007;17:5013-8
   Google Scholar
• Glaxo Group Ltd. Macrolide antibiotics. WO2002050092; 2002
   Google Scholar
• Andreotti D, Bientinesi I, Biondi S, A novel ketolide class: synthesis and antibacterial activity of a lead compound. Bioorg Med Chem Lett 2007;17:5265-9
   Google Scholar
• Hunziker D, Wyss P, Angehrn P, Novel ketolide antibiotics with a fused five-membered lactone ring – synthesis, physicochemical and antimicrobial properties. Bioorg Med Chem 2004;12:3503-19
   Google Scholar
• Enanta Pharmaceuticals, Inc. Novel 11,12-substituted lactone ketolide derivatives having antibacterial activity. WO2004016634; 2004
   Google Scholar
• Alpharma APS. 10-Substituted macrolide antibiotics. WO2004056843; 2004
   Google Scholar
• Undheim K, Gunnes S. Chemoselective synthesis of erythromycin A ketolides substituted in the C10-methyl group. Bioorg Med Chem 2007;15:119-29
   Google Scholar
• Lin X, Rico AC, Chu DT, Synthesis and antibacterial activity of C12 des-methyl ketolides. Bioorg Med Chem Lett 2006;16:4692-6
   PubMed Web of Science ®Google Scholar
• Burger MT, Hiebert C, Seid M, Synthesis and antibacterial activity of novel C12 ethyl ketolides. Bioorg Med Chem 2006;14:5592-604
   PubMed Web of Science ®Google Scholar
• Burger MT, Lin X, Chu DT, Synthesis and antibacterial activity of novel C12 vinyl ketolides. J Med Chem 2006;49:1730-43
   PubMed Web of Science ®Google Scholar
• Enanta Pharmaceuticals, Inc. 6,11 Bicyclic ketolide derivatives. WO2003097659; 2003
   Google Scholar
• Enanta Pharmaceuticals, Inc. Processes for the preparation of O-(2-aminobenzo[D]oxazol-5-yl methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182. US7563877; 2009
   Google Scholar
• Enanta Pharmaceuticals, Inc. Processes for the preparation of 2-fluoro 6-11 bicyclic erythromycin derivatives. WO2009137787; 2009
   Google Scholar
• Enanta Pharmaceuticals, Inc. Processes for the preparation of O-[5-[4-amino-thiazol-2-yl]-pyridin-2-ylmethyl]-hydroxylamine. WO2009137739; 2009
   Google Scholar
• Enanta Pharmaceuticals, Inc. 6, 11-4-Carbon bridged erythromycin derivatives. WO2004011009; 2004
   Google Scholar
• Enanta Pharmaceuticals, Inc. 6, 11-Bridged tricyclic macrolides. WO2007044927; 2007
   Google Scholar
• Ono T, Kashimura M, Suzuki K, In vitro and in vivo antibacterial activities of the tricyclic ketolide TE-802 and its analogs. J Antibiot 2004;57:518-27
   PubMedGoogle Scholar
• Enanta Pharmaceuticals, Inc. 3, 6-Bicyclolides. WO2006063039; 2006
   Google Scholar
• Gai Y, Tang D, Xu G, Synthesis of 3,6-bicyclolides: a novel class of macrolide antibiotics. Bioorg Med Chem Lett 2008;18:6315-8
   Google Scholar
• Tang D, Gai Y, Polemeropoulos A, Design, synthesis, and antibacterial activities of novel 3,6-bicyclolide oximes: length optimization and zero carbon linker oximes. Bioorg Med Chem Lett 2008;18:5078-82
   PubMed Web of Science ®Google Scholar
• Enanta Pharmaceuticals, Inc. 11, 12-Lactone bicyclolides. WO2006065721; 2006
   Google Scholar
• Enanta Pharmaceuticals, Inc. 3,6,11-Tricyclolide. WO2007115278; 2007
   Google Scholar
• Enanta Pharmaceuticals, Inc. Tetracyclic bicyclolides. WO2006065743; 2006
   Google Scholar
• Mutak S. Azalides from azithromycin to new azalide derivatives. J Antibiot 2007;60:85-122
   PubMed Web of Science ®Google Scholar
• Basnet DB, Park JW, Yoon YJ. Combinatorial biosynthesis of 5-O-desosaminyl erythronolide A as a potent precursor of ketolide antibiotics. J Biotechnol 2008;135:92-6
   Google Scholar
• Xu P, Liu L, Jin Z, Lei P. Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides. Bioorg Med Chem Lett 2007;17:3330-4
   Google Scholar
• Ranbaxy Laboratories Ltd. Erythromycin A derivatives as antibacterial agents. WO2006035301; 2006
   Google Scholar
• Liang J-H, Wang Y-Y, Zhu D-Y, Design, synthesis and antibacterial activity of a novel alkylide: 3-O-(3-aryl-propenyl)clarithromycin derivatives. J Antibiot 2009;62:605-11
   PubMed Web of Science ®Google Scholar
• Enanta Pharmaceuticals, Inc. Novel anhydrolide derivatives having antibacterial activity. WO2004069854; 2004
   Google Scholar
• Takashima H. Structural consideration of macrolide antibiotics in relation to the ribosomal interaction and drug design. Curr Topics Med Chem 2003;3:991-9
   PubMed Web of Science ®Google Scholar
• Ma C, Liu Z, Song H, Synthesis and antibacterial activity of novel 11,12-cyclic carbonate azithromycin 4″-O-carbamate derivatives. J Antibiot 2010;63:3-8
   PubMed Web of Science ®Google Scholar
• Ma S, Ma R, Liu Z, Synthesis and antibacterial activity of novel 15-membered macrolide derivatives: 4″-carbamate, 11,12-cyclic carbonate-4″-carbamate and 11,4″-di-O-arylcarbamoyl analogs of azithromycin. Eur J Med Chem 2009;44:4010-20
   Google Scholar
• Stimac V, Alihodzic S, Lazarevski G, Synthesis and biological properties of 4″-O-acyl derivatives of 8a-aza-8a-homoerythromycin. J Antibiot 2009;62:133-44
   Google Scholar
• Xu P, Liu L, Jin Z-P, Synthesis and antibacterial activity of 4″-O-heteroarylcarbamoyl derivatives of macrolide. Bioorg Med Chem Lett 2008;18:5507-11
   Google Scholar
• Wimberly BT. The use of ribosomal crystal structures in antibiotic drug design. Curr Opin Investig Drugs 2009;10:750-65
   Google Scholar
• Burak E, Bortolon E, Franceschi F, Enhanced macrolides: optimized molecular properties for oral exposure. 49th Interscience Conference on Antimicrobial Agents Chemotherapy. San Francisco, CA; 2009. p. F1-2049
   Google Scholar
• Kanyo Z, Bhattacharjee A, Chen S, Enhanced macrolides: overcoming resistance by improving target affinity. 49th Interscience Conference on Antimicrobial Agents Chemotherapy. San Francisco, CA; 2009. p. F1-2050
   Google Scholar
• Rib-X Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same. WO2008143730; 2008
   Google Scholar
• Rib-X Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same. WO2008106226; 2008
   Google Scholar
• Hanselmann R, Job GE, Johnson G, Synthesis of an antibacterial compound containing a 1,4-substituted 1H-1,2,3-triazole: a scaleable alternative to the “click” reaction. Org Proc Res Dev 2010;14:152-8
   Web of Science ®Google Scholar
• Heggelund A, Undheim K. Preparation of cyclic 2',3'-carbamate derivatives of erythromycin macrolide antibiotics. Bioorg Med Chem 2007;15:3266-77
   PubMed Web of Science ®Google Scholar
• Alpharma APS. Erythromycin derivatives as antibacterial agents. WO2006074962; 2006
   Google Scholar
• Dreier J, Amantea E, Kellenberger L, Page MGP. Activity of the novel macrolide BAL19403 against ribosomes from erythromycin-resistant Propionibacterium acnes. Antimicrob Agents Chemother 2007;51:4361-5
   PubMed Web of Science ®Google Scholar
• Falzari K, Zhu Z, Pan D, In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005;49:1447-54
   PubMed Web of Science ®Google Scholar
• Krajacic MB, Novak P, Dumic M, Novel ureas and thioureas of 15-membered azalides with antibacterial activity against key respiratory pathogens. Eur J Med Chem 2009;44:3459-70
   Google Scholar
• Creemer LC, Toth JE, Kirst HA. Synthesis and in vitro antimicrobial activity of 3-keto 16-membered macrolides derived from tylosin. J Antibiot 2002;55:427-36
   PubMed Web of Science ®Google Scholar
• Mutak S, Marsic N, Kramaric MD, Pavlovic D. Semisynthetic macrolide antibacterials derived from tylosin. Synthesis and structure-activity relationships of novel desmycosin analogues. J Med Chem 2004;47:411-31
   Google Scholar
• Terui Y, Kinoshita K, Kaneda Y, Synthesis of 2-methyl 16-membered macrolide derived from tylosin. J Antibiot 2006;59:98-104
   Google Scholar
• Yang B, Zollner T, Gebhardt P, Preparation and biological evaluation of novel leucomycin analogs derived from nitroso Diels-Alder reactions. Org Biomol Chem 2010;8:691-7
   Google Scholar
• Meiji Seika Kaisha, Ltd. 12-Oxy-13-amino-containing 16-membered cyclic macrolide derivative and process for producing the same. WO2006073172; 2006
   Google Scholar
• Miura T, Kurihara K, Furuuchi T, Novel 16-membered macrolides modified at C-12 and C-13 positions of midecamycin A1 and miokamycin. Part 1. Bioorg Med Chem 2008;16:3985-4002
   Google Scholar
• Furuuchi T, Miura T, Kurihara K, Design and synthesis of novel leucomycin analogues modified at the C-3 position. Part II. Bioorg Med Chem 2008;16:4401-18
   Google Scholar
• Meiji Seika Kaisha, Ltd. Novel 16-membered cyclic 4″-O-carbamoyl azalide derivative and process for producing the same. WO2007069555; 2007
   Google Scholar
• Miura T, Kanemoto K, Natsume S, Novel azalides derived from 16-membered macrolides. Part II. Bioorg Med Chem 2008;16:10129-56
   Google Scholar
• Miura T, Natsume S, Kanemoto K, Novel azalides derived from 16-membered macrolides. J Antibiot 2007;60:407-35
   PubMed Web of Science ®Google Scholar
• Enanta Pharmaceuticals, Inc. 3,6-Bridged tylosin derivatives. WO2008019240; 2008
   Google Scholar
• Intervet International B. V. Macrolide solid-state forms. WO2009013351; 2009
   Google Scholar
• Intervet International B. V. Macrolide synthesis process. WO2008012343; 2008
   Google Scholar
• Meiji Seika Kaisha, Ltd. Lincomycin derivatives and antibacterial agents containing the same as the active ingredient. WO2008146917; 2008
   Google Scholar
• Meiji Seika Kaisha, Ltd. Lincomycin derivative and antibacterial agent comprising the same as active ingredient. WO2008146919; 2008
   Google Scholar
• Meiji Seika Kaisha, Ltd. Lincomycin derivative and antibacterial agent containing the same as active ingredient. WO2007066805; 2007
   Google Scholar
• Ulanova D, Novotna J, Smutna Y, Mutasynthesis of lincomycin derivatives with activity against drug-resistant staphylococci. Antimicrob Agents Chemother 2010;54:927-30
   Google Scholar
• Held J, Westerman R, Kremsner PG, Mordmuller B. In vitro activity of mirincamycin (U24729A) against Plasmodium falciparum isolates in Gabon. Antimicrob Agents Chemother 2010;54:540-2
   Google Scholar
• Lee VJ. Anti-gram positive agents of natural product origins. In: Taylor JB, Triggle DJ, editors, Comprehensive medicinal chemistry II. Volume 7. Elsevier; 2007. p. 660-4
   Google Scholar
• Bacque E, Barriere J-C, Berthaud N. Recent progress in the field of antibacterial pristinamycins. Curr Med Chem Anti Infect Agents 2005;4:185-217
   Google Scholar
• Rangaraju M, Tarral A, Merdjan H, Optimization of the linopristin/flopristin dose ratio in NXL103. 49th Interscience Conference on Antimicrobial Agents Chemotherapy. San Francisco, CA; 2009. p. A1-1943
   Google Scholar
• Rangaraju M, Rabie W, Ponte N, A phase II double-blind, double-dummy, multicenter study of two doses of linopristin/flopristin (NXL103) vs. amoxicillin in the treatment of mild to moderate community acquired pneumonia (CAP) in adults. 49th Interscience Conference on Antimicrobial Agents Chemotherapy. San Francisco, CA; 2009. p. L1-336
   Google Scholar
• Politano AD, Sawyer RG. NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA. Curr Opin Investig Drugs 2010;11:225-36
   PubMed Web of Science ®Google Scholar
• Amsden GW. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005;55:10-21
   PubMed Web of Science ®Google Scholar
• Lopez-Boado YS, Rubin BK. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr Opin Pharmacol 2008;8:286-91
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 2008;31:12-20
   PubMed Web of Science ®Google Scholar